• Adverse Reactions of Ensartinib

  Ensartinib is a targeted therapy for ALK-positive non-small cell lung cancer (NSCLC). Common adverse reactions include gastrointestinal symptoms, abno···【Read More】

  Update: 2026-01-15Source: Haiou HealthViews: 191

• Ensartinib Dosage and Administration Instructions

  The recommended usual dose of ensartinib is 225 mg once daily, to be taken orally on an empty stomach (1 hour before a meal or 2 hours after a meal). ···【Read More】

  Update: 2026-01-15Source: Haiou HealthViews: 184

• Is Ensartinib a First, Second, or Third-Generation Targeted Drug?

  Ensartinib is a second-generation anaplastic lymphoma kinase (ALK) targeted drug, primarily indicated for the treatment of ALK-positive non-small cell···【Read More】

  Update: 2026-01-14Source: Haiou HealthViews: 184

• Ensartinib Package Insert

  Ensartinib is an anaplastic lymphoma kinase (ALK)-targeted oral capsule developed by Hutchison MediPharma. It was first approved for marketing in Chin···【Read More】

  Update: 2026-01-14Source: Haiou HealthViews: 230

• What are the basic information of Zebutinib drugs?

  Zanubrutinib is an oral small molecule targeted drug, belonging to the Bruton tyrosine kinase (BTK) inhibitor, mainly used for the treatment of hemato···【Read More】

  Update: 2026-10-10Source: Haiou HealthViews: 71

• What are the usage, dosage, and special population medication of Zebutinib?

  Zebutinib is a novel BTK inhibitor that inhibits BTK activity by covalently binding to cysteine at position 481 of the BTK protein, thereby suppressin···【Read More】

  Update: 2026-10-10Source: Haiou HealthViews: 71

• Drug instructions for Zebutinib

  Zebutinib is a novel BTK inhibitor that inhibits BTK activity by covalently binding to cysteine at position 481 of the BTK protein, thereby suppressin···【Read More】

  Update: 2026-10-10Source: Haiou HealthViews: 71

• Basic detailed information of Xidabenzamide

  Cidabetamide is a prescription anti-cancer drug, mainly used for peripheral T-cell lymphoma and specific types of breast cancer. It must be used under···【Read More】

  Update: 2026-10-09Source: Haiou HealthViews: 72

• What are the indications and mechanisms of action for Chidamide and Ampusa?

  Chidamide (trade name "Epidaza"), a national Class 1 original new drug, is a new molecular entity drug exclusively discovered by the company···【Read More】

  Update: 2026-10-09Source: Haiou HealthViews: 72

• Instructions for Chidamide (Aptamil): Indications - Dosage - Adverse Reactions

  As the first original new chemical drug approved for marketing in China and the first oral, subtype selective histone deacetylase (HDAC) inhibitor in ···【Read More】

  Update: 2026-10-09Source: Haiou HealthViews: 72

• What is the mechanism of action of Furmonertinib

  What is the mechanism of action of Furmonertinib and Furmonertinib? Furmonertinib is a novel epidermal growth factor receptor (EGFR) tyrosine kinase i···【Read More】

  Update: 2026-09-30Source: Haiou HealthViews: 80

• What is the basic information of Furmonertinib?

  Firmonertinib is an oral, brain penetrative, and mutation selective EGFR inhibitor. It targets multiple EGFR mutations, including exon 20 insertion an···【Read More】

  Update: 2026-09-30Source: Haiou HealthViews: 82

• What are the indications for Fumatinib?

  Furmonertinib is a third-generation EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor) primarily used for the treatment of locally ···【Read More】

  Update: 2026-09-30Source: Haiou HealthViews: 81

• Key information sorting of Taletrectinib

  Taletrectinib was approved for marketing in China in December 2024, becoming the second targeted therapy for ROS1 positive non-small cell lung cancer ···【Read More】

  Update: 2026-09-29Source: Haiou HealthViews: 86

• What are the advantages of taletractinib?

  Teratinib, as a new generation ROS1 inhibitor, is a masterpiece of the medical community's precise efforts to address the important pathogenic mec···【Read More】

  Update: 2026-09-29Source: Haiou HealthViews: 85